Beckley Retreats Launches Signature Program for Personal Discovery and Transformation
28 nov. 2023 09h00 HE
|
Beckley Retreats
NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Beckley Retreats, a psilocybin retreats and holistic wellbeing company, announced today the launch of its Signature Program for Personal Discovery and...
Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing
28 nov. 2023 07h42 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health...
PharmAla Partners with Clariti Strategic Advisors™
08 nov. 2023 08h55 HE
|
PharmAla Biotech
PharmAla signs long-term partnership with Clariti Strategic Partners as its investment banking and advisory firm
PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa
07 nov. 2023 08h55 HE
|
PharmAla Biotech
PharmAla completes the historic first shipment of MDMA and Psilocybin to its Australian Joint Venture, Cortexa, for use in commercial patient treatments
Optimi Health Welcomes Dr. Preston A. Chase as New Chief Science Officer
07 nov. 2023 07h30 HE
|
Optimi Health Corp.
Optimi Health Introduces New Chief Science Officer Dr. Preston A. Chase.
Lucy Scientific Discovery’s Alternative Mental Health Treatments to Provide Opportunity to Improve Mental Health
18 oct. 2023 07h00 HE
|
Lucy Scientific Discovery Inc.
From herbal remedies to psychedelics, like psilocybin and MDMA, Lucy Scientific is working to provide the ingredients for groundbreaking mental health ther
PharmAla Receives First Office Action for PharmAla-1 PCT Filing
25 sept. 2023 08h55 HE
|
PharmAla Biotech
PharmAla has recieved a positive First Office Action on its novel P-1 Molecule from the Patent Cooperation Treaty
Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial
14 sept. 2023 14h59 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased...
Psychedelic Drugs Market revenue to exceed USD 12 Billion by 2035, says Research Nester
12 sept. 2023 09h38 HE
|
Research Nester
New York, Sept. 12, 2023 (GLOBE NEWSWIRE) -- The global psychedelic drugs market size is predicted to grow at a CAGR of over ~ 14% from 2023 to 2035. The market is projected to garner a revenue of...
Optimi Health Granted Amendment to Dealer's Licence by Health Canada to Supply Special Access Program
07 sept. 2023 07h30 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, proudly...